4basebio Enhances Strategic Direction with Expert Advisory Board Formation

4basebio, a biotechnology company based in Cambridge, is advancing its mission to accelerate the development of advanced therapy medicinal products (ATMPs) through its innovative synthetic DNA products and non-viral nucleic acid delivery platforms. The company aims to lead the market in manufacturing and supplying high-quality synthetic DNA for research, therapeutic, and pharmacological applications, while also developing targeted non-viral vectors for efficient delivery of therapeutic payloads in patients.

In a strategic move to bolster its expertise, 4basebio recently established a Strategic Advisory Board, welcoming industry veterans Bertrand Coissac, Lawrence Pitcher, and Deborah Barbara. This newly formed board is set to provide valuable guidance as 4basebio continues to expand its capabilities and influence in the life sciences sector.

Bertrand Coissac, CEO of Twogene, brings a wealth of experience in cell and gene therapy manufacturing. His previous role as Vice President of Corporate Development at Polyplus, which was acquired by Sartorius in July 2023, underscores his deep industry knowledge and strategic insight.

Lawrence Pitcher, Vice President and General Manager of Maryland Gene Therapy Sites at Catalent Pharma Solutions, adds substantial operational and business acumen to the board. Pitcher's experience includes leadership roles at Thermo Fisher Scientific, where he managed the Advanced Therapies business.

Deborah Barbara, with over three decades of experience in the life sciences industry, most recently served as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Her extensive background includes leadership positions at Thermo Fisher Scientific, where she was General Manager of the Nucleic Acid Therapeutics business.

Dr. Walker, a seasoned professional in life sciences with a robust portfolio of scientific publications and patents, continues to contribute her expertise to 4basebio while also serving as a non-executive director for two other high-growth healthcare companies.

With the formation of its Strategic Advisory Board, 4basebio is poised to strengthen its position in the biotechnology field, driving forward its vision of becoming a leader in synthetic DNA production and innovative therapeutic delivery systems.